East Asian mtDNA haplogroup determination in Koreans: haplogroup-level coding region SNP analysis and subhaplogroup-level control region sequence analysis

The present study analyzed 21 coding region SNP markers and one deletion motif for the determination of East Asian mitochondrial DNA (mtDNA) haplogroups by designing three multiplex systems which apply single base extension methods. Using two multiplex systems, all 593 Korean mtDNAs were allocated into 15 haplogroups: M, D, D4, D5, G, M7, M8, M9, M10, M11, R, R9, B, A, and N9. As the D4 haplotypes occurred most frequently in Koreans, the third multiplex system was used to further define D4 subhaplogroups: D4a, D4b, D4e, D4g, D4h, and D4j. This method allowed the complementation of coding region information with control region mutation motifs and the resultant findings also suggest reliable control region mutation motifs for the assignment of East Asian mtDNA haplogroups. These three multiplex systems produce good results in degraded samples as they contain small PCR products (101-154 bp) for single base extension reactions. SNP scoring was performed in 101 old skeletal remains using these three systems to prove their utility in degraded samples. The sequence analysis of mtDNA control region with high incidence of haplogroup-specific mutations and the selective scoring of highly informative coding region SNPs using the three multiplex systems are useful tools for most applications involving East Asian mtDNA haplogroup determination and haplogroup-directed stringent quality control.     

Zirconium tetrachloride revisited

Zirconium tetrachloride, ZrCl₄, is a strategic material with wide‐ranging applications. Until now, only one crystallographic study on ZrCl₄ has been reported [Krebs (1970). Z. Anorg. Allg. Chem. 378 , 263–272] and that was more than 40 years ago. The compound used for the previous determination was prepared from ZrO₂ and Cl₂–CCl₄, and single‐crystal X‐ray diffraction (SCXRD) studies on ZrCl₄ obtained from Zr metal have not yet been reported. In this context, we prepared ZrCl₄ from the reaction of Zr metal and Cl₂ gas in a sealed tube and investigated its structure at 100, 150, 200, 250, and 300 K. At 300 K, the SCXRD analysis indicates that ZrCl₄ crystallizes in the orthorhombic space group Pca2₁ [a = 6.262 (9), b = 7.402 (11), c = 12.039 (17) Å, and V = 558.0 (14) ų] and consists of infinite zigzag chains of edge‐sharing ZrCl₆ octahedra. This chain motif is similar to that observed previously in ZrCl₄, but the structural parameters and space group differ. In the temperature range 100–300 K, no phase transformation was identified, while elongation of intra‐chain Zr…Zr [3.950 (1) Å at 100 K and 3.968 (5) Å at 300 K] and inter‐chain Cl…Cl [3.630 (3) Å at 100 K and 3.687 (9) Å at 300 K] distances occurred.     

预测新的生物胺受体配基结合位点

生物胺受体被认为是一类重要的药物靶标,用生物信息学手段寻找它的配基结合位点并分析其功能,对于药物设计具有重要的指导意义.从整体上结合可变性、疏水性和保守性构建了受体的2D螺旋横切面模型,预测出其可能的配基结合区Ⅰ、Ⅱ,其中TM3、TM4以及TM7在配基结合中起关键作用,E-Ⅱ环也参与了配基结合这一过程,这是对以往普遍认为只有TM参与配基结合的延伸.从局部上寻找了生物胺受体及其子受体的基序,提出了家族可变亚家族保守基序(motif)概念,即家族可变区中找到的亚家族保守的基序.最后结合整体与局部分析结果分析了各基序的功能,预测了行使配基结合功能的基序及其相应位点,结果证明与突变实验结果有很好的吻合度.     

Refolding of a Staphylokinase Variant Y1-Sak by Reverse Dilution

To develop more potent thrombolytic agents with fibrinolytic and antiplatelet aggregation activity, staphylokinase (Sak) variant Y1-Sak, a recombinant mutant of the Staphylococcus aureus protein Sak, was constructed. Y1-Sak formed an insoluble inclusion body when overexpressed in Escherichia coli strain JF1125. To obtain an optimized refolding process, dilution refolding was used to optimize refolding conditions. The results revealed that additive l-arginine and refolding temperature played critical roles in the refolding of Y1-Sak. Subsequently, two refolding methods, gel filtration and reverse dilution, were investigated to refold Y1-Sak. The results indicated that the fibrinolytic activity and recovery of Y1-Sak from gel filtration were lower than those from reverse dilution. Reverse dilution refolding successfully reduced the side reaction of refolding with the help of l-arginine, and the fibrinolytic activity and recovery of Y1-Sak were significantly improved. Functional analysis revealed that refolded Y1-Sak by reverse dilution possessed fibrinolytic and antiplatelet aggregation activities. Moreover, the immunogenicity of Y1-Sak was significantly reduced.     

学龄儿童智商与微量元素含量关系研究

为了解头发微量元素含量与学龄儿童智商之间的关系,本文测定了深圳市某小学570名7－13岁低智商儿童和正常儿童的IQ值及其头发中七种元素（I、Zn、Fe、Cu、Ca、Mn、Pb）的含量,并对低智商儿童及正常儿童头发中的元素含量作了比较。结果表明,低智商儿童头发碘、锌、钙的含量显著低于正常儿童头发中的含量,而发铅则显著高于正常儿童的含量。说明儿童智商高低与机体碘、锌、钙以及铅的含量有密切关系。     

Cyclic RGD–Polyethylene Glycol–Polyethylenimine for Intracranial Glioblastoma‐Targeted Gene Delivery

Even though the blood–brain barrier (BBB) is compromised for angiogenesis, therapeutic agents for glioblastoma multiforme (GBM) are particularly inefficient due to the existence of a blood–tumor barrier (BTB), which hampers tumor accumulation and uptake. Integrin α_vβ₃ is overexpressed on glioblastoma U87 cells and neovasculture, thus making its ligands such as the RGD motif target glioblastoma in vitro and in vivo. In the present work, we have designed a modified polyethylene glycol–polyethylenimine (PEG–PEI) gene carrier by conjugating it with a cyclic RGD sequence, c(RGDyK) (cyclic arginine‐glycine‐aspartic acid‐D ‐tyrosine‐lysine). When complexed with plasmid DNA, this gene carrier, termed RGD–PEG–PEI, formed homogenous nanoparticles with a mean diameter of 73 nm. These nanoparticles had a high binding affinity with U87 cells and facilitated targeted gene delivery against intracranial glioblastoma in vivo, thereby leading to a higher gene transfer efficiency compared to the PEG–PEI gene carrier without RGD decoration. This intracranial glioblastoma‐targeted gene carrier also enhanced the therapeutic efficacy of pORF‐hTRAIL, as evidenced by a significantly prolonged survival of intracranial glioblastoma‐bearing nude mice. Considering the contribution of glioblastoma neovasculature to the BBB under angiogenic conditions, our results demonstrated the therapeutic feasibility of treating a brain tumor through mediation of integrin α_vβ₃, as well as the potential of using RGD–PEG–PEI as a targeted gene carrier in the treatment of intracranial glioblastoma.